Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 86.27

+6.0%

Jan 7 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (2771)	6/17/2010 11:47:01 AM
From: Jibacoa	1 Recommendation of 3722

IMGN dipped below the support at the $8 level on June 9 and is now trying to test the resistance at $9 <g> The stock is still up 1.85% on moderate volume about 1/5 its ADV bigcharts.marketwatch.com IMGN presented data of its IMGN388 at the ASCO meeting. The data that was reported, Abstract #3058, was from the first clinical trial conducted with IMGN388. IMGN388 has demonstrated favorable tolerability at the dose levels evaluated to date, and higher doses are now starting to be evaluated. IMGN388 is in development for the treatment of solid tumors. It utilizes the TAP technology. which consists of IMGN’s DM4 agent attached to an av integrin-targeting antibody using IMGN's method of attachment. The antibody component serves to target IMGN388 to av integrin-expressing cells and the DM4 serves to kill these cells.<g> IMGN has continued to reported lower revenues and higher losses. The EL for 2010 is around $0.90 vs. $0.62 in 2009 The ACTAY is $12.58 But it seems better to wait for further developments and see if the stock can close above the $9 and $10 resistance levels.<g> bigcharts.marketwatch.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next